Mouse Anti-Human CYFRA21-1 monoclonal antibody, clone 2714

Aiming to develop a stable and simple immunosensor with superior performance, we designed a new strategy based on complexation competition reaction among CaCO3, zeolitic imidazolate framework (ZIF)-8 and ethylenediamine tetraacetic acid disodium (EDTA) for electrochemical detection of cytokeratin 19 fragment 21-1 (CYFRA21-1). First, immunocomplex was formed by CaCO3-Au modified with antibody, MBs modified with antibody and antigen in tube. Then, excess EDTA was added for complexation reaction with CaCO3 and supernatant containing EDTA without complexation reaction was obtained. Second, Ag nanoparticles (NPs) as signal substance were electrodeposited on the electrode surface, and silenced by ZIF-8 layer generated in situ. The remained EDTA in supernatant was transferred to electrode for etching ZIF-8. The signal of Ag NPs was reactivated, owning to partly removing silencing layer of ZIF-8. Therefore, the concentration of target analyte was quantitatively detected by measuring the current signal of Ag/AgCl. Under optimal conditions, the electrochemical immunosensor had an ultralow detection limit of 3.175 fg mL(-1) for CYFRA21-1, with a wide detection range from 10 fg mL(-1) to 1 mu g mL(-1). This work successfully constructed an immunosensor based on complexation competition reaction, which providing a potential route for clinical analysis.

Background/Aim: Few data are available regarding the clinical performance of LOCI (TM)-based tumor marker assays. We investigated the diagnostic power of carcinogenic antigen, carbohydrate antigen 19-9, carbohydrate antigen 15-3, carbohydrate antigen 125 and alpha-fetoprotein for detection of gastrointestinal (GI) cancer. Patients and Methods: We analyzed sera from 204 patients (107 with GI cancer, 73 with benign GI diseases and 24 healthy controls) using the Dimension (TM) Vista1500 analyzer. Results: Levels of biomarkers in healthy controls were in the expected ranges and were only slightly higher in benign GI controls. Established tumor-type-associated markers were elevated in specific cancer types and discriminated well between cancer and benign controls. Best performance was found for CEA in colorectal cancer (area under the curve=0.84, sensitivity=51.7% at 95% specificity vs. benign), CA19-9 in gallbladder/pancreatic cancer (AUC=0.85, sensitivity=60.6%) and AFP in liver cancer (AUC=0.87, sensitivity=68.4%). Conclusion: Our study demonstrated the high diagnostic power of well-known biomarkers. LOCI (TM)-based tumor marker assays give reliable results in routine diagnostics.